The global progressive multifocal leukoencephalopathy (PML) drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Progressive multifocal leukoencephalopathy (PML) is a rare brain infection that affects the substance in the brain that protects nerve cells. The infection gets worse over time and leads to neurological disabilities. The major factor driving the demand for PML drugs is significant prevalence of this infection across the globe. 

According to the National Organization for Rare Disorder (NORD), PML is caused by a virus called JC virus (JCV). JCV is found in 85% of the adult population globally. Additionally, PML occurs in approximately one in 200,000 people. Furthermore, in the US and Europe, an estimated 4,000 people develop PML each year. Hence, the rising prevalence of the infection is driving the demand for progressive multifocal leukoencephalopathy drugs.

Some major players in the market include Pfizer, Inc., F. Hoffman - La Roche AG, and Bristol-Myers Squibb Co., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Cellevolve Bio announced a collaboration with Australia-based QIMR Berghofer Medical Research Institute and its cell therapy manufacturing facility Q-Gen Cell Therapeutics. The collaboration was aimed to advance a novel off-the-shelf t-cell therapy in the first randomized cell therapy trial for progressive multifocal leukoencephalopathy (PML).

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Pfizer, Inc., F. Hoffman - La Roche AG, and Bristol-Myers Squibb Co., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Progressive Multifocal Leukoencephalopathy Drug Market Report by Segment

By Type

• EBT-103
• IKT-01427
• Imatinib Mesylate
• NI-307
• Others

By Application 

• Hospital
• Clinic 
• Others

Global Progressive Multifocal Leukoencephalopathy Drug Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa